CARDIOVASCULAR
ENGINEERING
Journal for Extracorporeal Circulation, Assist Devices,Transplantation and Artificial Organs
|
|
CARDIOVASCULAR
|
Volume 2, 1997, No 3 |
Abstract:
Background: Fibrin sealant is used in cardiovascular and thoracic
surgery as a hemostatic and adhesive agent and as a sealant of
pulmonary air leak. Conventional fibrin sealants based on human
fibrinogen prepared from pooled plasma donations and thrombin
have not been licensed in several countries including the US
because of concerns about infection. Methods: The Vivostat system
is a new medical device for the preparation of an autologous
fibrin sealant in the operating room. The system is fully
automated and microprocessor controlled and incorporates three
components: an automated processor unit, an automated applicator
unit, and a disposable, single patient use unit which includes a
prep set and a spraypen applicator. The biochemical process is
initiated by batroxobin, which acts upon fibrinogen from the
patient's plasma. The completion of the process depends entirely
on endogenous thrombin in producing the sealant. No exogenous
thrombin is added. Results: The preparation process was completed
in 30 min. From 120 ml of the patient's blood the yield was 4.5
+/- 0.3 ml (mean +/- standard deviation) of fibrin sealant.
Conclusion: It is possible to prepare autologous fibrin sealant
with the Vivostat system in 30 minutes. No exogenous thrombin is
added. The sealant can be used in cardiovascular surgery.
Keywords:
autologous fibrin sealant, batroxobin, cardiovascular surgery,
hemostasis, fibrinogen, microprocessor, thrombin
Address for Correspondence:
Reference:
(CVE. 1997; 2 (3): 204-206)
[Pabst Science Publishers] [CVE Homepage] [Contents] [Editorials] [Masthead] [Search] [Orders]
PABST SCIENCE PUBLISHERS
Lengerich, Berlin, Düsseldorf,
Leipzig, Riga, Scottsdale AZ (USA),
Wien, Zagreb